European Archives - Page 436 of 1108 - European Medical Journal

Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study

Chronic spontaneous urticaria (CSU) is characterised by the spontaneous occurrence of wheals (hives) and/or angioedema for ≥6 weeks.1 CSU can persist for several years and is associated with severe pruritus. Skin mast cell activation in CSU occurs via Type I autoallergy driven by IgE to autoallergens, and a Type IIb autoimmune response due to mast cell-targeted autoantibodies against IgE or high-affinity IgE receptor.

EADV 2022 Abstract Highlights

The following highlights spotlight abstracts presented at the European Academy of Dermatology and Venereology (EADV) Congress 2022, specifically focusing on the latest developments in nail disorders and urticaria.

Updates on Best Practices for Onychomycosis: Hitting the Nail on the Head

DURING the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress, 7th–10th September 2022, held both in-person in Milan, Italy, and virtually, experts delivered a session on the topic of nail disorders.

Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase III Trials

The primary endpoint analyses from the SUNSHINE and SUNRISE Phase III trials of secukinumab in moderate-to-severe hidradenitis suppurativa (HS) were featured in an oral presentation as part of the late-breaking news session at the 31st annual European Academy of Dermatology and Venereology (EADV) congress. Known collectively as the SUNNY trials, the SUNSHINE and SUNRISE studies represent the largest Phase III trials conducted in HS to date.

EADV Interview: Christa De Cuyper

EMJ spoke to Christa De Cuyper about her roles within the European Academy of Dermatology and Venereology (EADV), including the recent Nurses in Dermatology Practice event, which De Cuyper co-chaired.

Global TB Summit 2022: What to expect?

Watch the video to learn more about the annual Global TB Clinical and Educational Summit.

Embracing pharma's digital transformation

In his first regular column for GOLD, Davidek Herron discusses digital transformation in pharma and pursuing operational excellence.

An opportunity to crack the opioid crisis

With opioid abuse showing little sign of abating, what role can pharma play in addressing the crisis?

Meet GOLD's next catalyst – Reshema Kemps-Polanco

Helena and Isabel speak to GOLD catalyst interviewee Reshema Kemps-Polanco, Executive Vice President and US Head, Novartis Oncology.

Review of the European Respiratory Society (ERS) International Congress 2022

PRESENTED in a hybrid format for the first time, this year’s European Respiratory Society (ERS) International Congress welcomed over 19,000 respiratory professionals, with over 10,000 attending in-person in Barcelona, Spain. Known for its stunning buildings, Barcelona is home to many unusual architectural wonders, including Antoni Gaudí’s Casa Batlló, which was classified as a UNESCO World Heritage Site in 2005.